Milestone Pharmaceuticals...

NASDAQ: MIST · Real-Time Price · USD
1.74
0.00 (0.00%)
At close: Jun 06, 2025, 3:59 PM
1.71
-1.44%
After-hours: Jun 06, 2025, 05:49 PM EDT

Milestone Pharmaceuticals Statistics

Share Statistics

Milestone Pharmaceuticals has 53.46M shares outstanding. The number of shares has increased by 0.18% in one year.

53.46M
0.18%
0.05%
37.09%
n/a
13,230
0.53%

Short Selling Information

The latest short interest is 1.97M, so 3.68% of the outstanding shares have been sold short.

1.97M
3.68%
3.68%
1.81

Valuation Ratios

The PE ratio is -3.54 and the forward PE ratio is -1.7. Milestone Pharmaceuticals's PEG ratio is 0.07.

-3.54
-1.7
0
0.6
11.17
-5.08
0.07
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Milestone Pharmaceuticals.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 9.1, with a Debt / Equity ratio of 4.17.

9.1
9.1
4.17
-1.3
-1.9
11.76

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1,258,151.52
33
0
n/a

Taxes

-259K
0.62%

Stock Price Statistics

The stock price has increased by 16.89% in the last 52 weeks. The beta is 0.92, so Milestone Pharmaceuticals's price volatility has been higher than the market average.

0.92
16.89%
1.21
1.64
67.18
2,472,947

Income Statement

n/a
n/a
-42.1M
-41.52M
-42.1M
-38.2M
-0.67
Full Income Statement

Balance Sheet

The company has 25.31M in cash and 54.8M in debt, giving a net cash position of -29.48M.

25.31M
54.8M
-29.48M
-367.55M
61.88M
47.51M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -28.85M and capital expenditures -33K, giving a free cash flow of -28.88M.

-28.85M
-33K
-28.88M
-0.46
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

MIST does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for MIST is $7, which is 304.6% higher than the current price. The consensus rating is "Buy".

$7
304.6%
Buy
2
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

-9.8
1